Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism

Ilia G. Halatchev, Kate L J Ellacott, Wei Fan, Roger D. Cone

Research output: Contribution to journalArticle

189 Citations (Scopus)

Abstract

Peptide YY3-36 (PYY3-36), a pepticle released postprandially by the gut, has been demonstrated to inhibit food intake. Little is known about the mechanism by which PYY3-36 inhibits food intake, although the peptide has been shown to increase hypothalamic proopiomelanocortin (POMC) mRNA in vivo and to activate POMC neurons in an electrophysiological slice preparation. Understanding the physiology of PYY3-36 is further complicated by the fact that some laboratories have had difficulty demonstrating inhibition of feeding by the peptide in rodents. We demonstrate here that, like cholecystokinin, PYY3-36 dose-dependently inhibits food intake by approximately 20-45% over a 3- to 4-h period post ip administration, with no effect on 12-h food intake. This short-lived satiety effect is not seen in animals that are not thoroughly acclimated to handling and ip injection, thus potentially explaining the difficulty in reproducing the effect. Surprisingly, PYY3-36 was equally efficacious in inducing satiety in wildtype and melanocortin-4 receptor (MC4-R)-deficient mice and thus does not appear to be dependent on MC4-R signaling. The expression of c-Fos, an indirect marker of neuronal activation, was also examined in forsbrain and brainstem neurons after ip treatment with a dose of PYY3-36 shown to induce satiety. The peptide induced no significant neuronal activation in the brainstem by this assay, and only modest activation of hypothalamic POMC neurons. Thus, unlike cholecystokinin, PYY3-36-induced satiety is atypical, because it does not produce detectable activation of brainstem satiety centers and is not dependent on MC4-R signaling.

Original languageEnglish (US)
Pages (from-to)2585-2590
Number of pages6
JournalEndocrinology
Volume145
Issue number6
DOIs
StatePublished - Jun 2004

Fingerprint

Receptor, Melanocortin, Type 4
Eating
Pro-Opiomelanocortin
Brain Stem
Cholecystokinin
Neurons
Peptides
peptide YY (3-36)
Rodentia
Messenger RNA
Injections

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. / Halatchev, Ilia G.; Ellacott, Kate L J; Fan, Wei; Cone, Roger D.

In: Endocrinology, Vol. 145, No. 6, 06.2004, p. 2585-2590.

Research output: Contribution to journalArticle

Halatchev, Ilia G. ; Ellacott, Kate L J ; Fan, Wei ; Cone, Roger D. / Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism. In: Endocrinology. 2004 ; Vol. 145, No. 6. pp. 2585-2590.
@article{cea98021e3a747298f8c47996c01135f,
title = "Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism",
abstract = "Peptide YY3-36 (PYY3-36), a pepticle released postprandially by the gut, has been demonstrated to inhibit food intake. Little is known about the mechanism by which PYY3-36 inhibits food intake, although the peptide has been shown to increase hypothalamic proopiomelanocortin (POMC) mRNA in vivo and to activate POMC neurons in an electrophysiological slice preparation. Understanding the physiology of PYY3-36 is further complicated by the fact that some laboratories have had difficulty demonstrating inhibition of feeding by the peptide in rodents. We demonstrate here that, like cholecystokinin, PYY3-36 dose-dependently inhibits food intake by approximately 20-45{\%} over a 3- to 4-h period post ip administration, with no effect on 12-h food intake. This short-lived satiety effect is not seen in animals that are not thoroughly acclimated to handling and ip injection, thus potentially explaining the difficulty in reproducing the effect. Surprisingly, PYY3-36 was equally efficacious in inducing satiety in wildtype and melanocortin-4 receptor (MC4-R)-deficient mice and thus does not appear to be dependent on MC4-R signaling. The expression of c-Fos, an indirect marker of neuronal activation, was also examined in forsbrain and brainstem neurons after ip treatment with a dose of PYY3-36 shown to induce satiety. The peptide induced no significant neuronal activation in the brainstem by this assay, and only modest activation of hypothalamic POMC neurons. Thus, unlike cholecystokinin, PYY3-36-induced satiety is atypical, because it does not produce detectable activation of brainstem satiety centers and is not dependent on MC4-R signaling.",
author = "Halatchev, {Ilia G.} and Ellacott, {Kate L J} and Wei Fan and Cone, {Roger D.}",
year = "2004",
month = "6",
doi = "10.1210/en.2003-1754",
language = "English (US)",
volume = "145",
pages = "2585--2590",
journal = "Endocrinology",
issn = "0013-7227",
publisher = "The Endocrine Society",
number = "6",

}

TY - JOUR

T1 - Peptide YY3-36 inhibits food intake in mice through a melanocortin-4 receptor-independent mechanism

AU - Halatchev, Ilia G.

AU - Ellacott, Kate L J

AU - Fan, Wei

AU - Cone, Roger D.

PY - 2004/6

Y1 - 2004/6

N2 - Peptide YY3-36 (PYY3-36), a pepticle released postprandially by the gut, has been demonstrated to inhibit food intake. Little is known about the mechanism by which PYY3-36 inhibits food intake, although the peptide has been shown to increase hypothalamic proopiomelanocortin (POMC) mRNA in vivo and to activate POMC neurons in an electrophysiological slice preparation. Understanding the physiology of PYY3-36 is further complicated by the fact that some laboratories have had difficulty demonstrating inhibition of feeding by the peptide in rodents. We demonstrate here that, like cholecystokinin, PYY3-36 dose-dependently inhibits food intake by approximately 20-45% over a 3- to 4-h period post ip administration, with no effect on 12-h food intake. This short-lived satiety effect is not seen in animals that are not thoroughly acclimated to handling and ip injection, thus potentially explaining the difficulty in reproducing the effect. Surprisingly, PYY3-36 was equally efficacious in inducing satiety in wildtype and melanocortin-4 receptor (MC4-R)-deficient mice and thus does not appear to be dependent on MC4-R signaling. The expression of c-Fos, an indirect marker of neuronal activation, was also examined in forsbrain and brainstem neurons after ip treatment with a dose of PYY3-36 shown to induce satiety. The peptide induced no significant neuronal activation in the brainstem by this assay, and only modest activation of hypothalamic POMC neurons. Thus, unlike cholecystokinin, PYY3-36-induced satiety is atypical, because it does not produce detectable activation of brainstem satiety centers and is not dependent on MC4-R signaling.

AB - Peptide YY3-36 (PYY3-36), a pepticle released postprandially by the gut, has been demonstrated to inhibit food intake. Little is known about the mechanism by which PYY3-36 inhibits food intake, although the peptide has been shown to increase hypothalamic proopiomelanocortin (POMC) mRNA in vivo and to activate POMC neurons in an electrophysiological slice preparation. Understanding the physiology of PYY3-36 is further complicated by the fact that some laboratories have had difficulty demonstrating inhibition of feeding by the peptide in rodents. We demonstrate here that, like cholecystokinin, PYY3-36 dose-dependently inhibits food intake by approximately 20-45% over a 3- to 4-h period post ip administration, with no effect on 12-h food intake. This short-lived satiety effect is not seen in animals that are not thoroughly acclimated to handling and ip injection, thus potentially explaining the difficulty in reproducing the effect. Surprisingly, PYY3-36 was equally efficacious in inducing satiety in wildtype and melanocortin-4 receptor (MC4-R)-deficient mice and thus does not appear to be dependent on MC4-R signaling. The expression of c-Fos, an indirect marker of neuronal activation, was also examined in forsbrain and brainstem neurons after ip treatment with a dose of PYY3-36 shown to induce satiety. The peptide induced no significant neuronal activation in the brainstem by this assay, and only modest activation of hypothalamic POMC neurons. Thus, unlike cholecystokinin, PYY3-36-induced satiety is atypical, because it does not produce detectable activation of brainstem satiety centers and is not dependent on MC4-R signaling.

UR - http://www.scopus.com/inward/record.url?scp=2542444495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542444495&partnerID=8YFLogxK

U2 - 10.1210/en.2003-1754

DO - 10.1210/en.2003-1754

M3 - Article

C2 - 15016721

AN - SCOPUS:2542444495

VL - 145

SP - 2585

EP - 2590

JO - Endocrinology

JF - Endocrinology

SN - 0013-7227

IS - 6

ER -